Mylan Laboratories Inc. , is a leading pharmaceutical company that develops, manufacturers and markets generic and proprietary prescription pharmaceutical products. For more information, ultram no prescription visit www. We continue development of a FlashDose(R) ultram no prescription form of a tramadol/acetaminophen combination product. Subject to FDA approval, Ralivia(TM) FlashDose(R) will be available in 50mg, tablets by prescription only.
The oral analgesic market generated nearly $575 million from retail prescriptions during the 12-month period ending October 1997, an increase of 18 percent from the prior year, according to Scott-Levin. It accounted for 72% of the 326,000 details made for oral non-narcotic analgesics during the quarter ending October 1997. We assume no obligation to update any forward-looking statements Ultram no prescription presented here today, whether as a result of new information, future events or otherwise. Since then, Duract has continued to gain new prescription share (27% ultram no prescription in October) from market leader Ultram and third-place Cataflam. Tramadol is currently sold in the United States under the brand name Ultram(R) with approximately 11 million prescriptions dispensed during for the twelve months ended December 31, 2003 including ultram no prescription generics. The combined market for narcotic and non-narcotic analgesics generated sales of $13. 9 billion in ultram no prescription the United States for this same time period. Wyeth's Duract details mainly targeted primary care physicians, who received 54% of the total, and orthopedic surgeons, who received 18%. The oral analgesic market generated nearly ultram no prescription $575 million from retail prescriptions during the 12-month period ending October 1997, an increase of 18% from the prior year.
The other 62 patients received drugs at their doctors' discretion. To the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. After only 3 months on the market, Duract became the most promoted product in its class. The drug captured 19 percent of new prescriptions in its Ultram no prescription category in August 1997, according to Scott-Levin's Source Prescription Audit.